近日，百济神州发布公告称，依托百济神州研发、生产、商业化全链自主优势，百悦达 在获批8天后迅 速实现商业化供应并投入临床使用，惠及中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤及套细胞淋巴瘤 成人患者。 ...

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical sector, with the overall performance of the Shenwan Pharmaceutical and Biological Index increasing by 7.8% during the week, outperforming the Shanghai Composite Index which rose by 3.82% [2][3]. Core Insights - The pharmaceutical sector's overall valuation stands at 30.6 times earnings, ranking 10th among 31 Shenwan primary industries [5]. - The report highlights significant developments in the long-term care insurance system transitioning from pilot programs to full establishment during the 14th Five-Year Plan, with coverage reaching nearly 300 million people and fund expenditures exceeding 100 billion yuan by the end of 2025 [11]. - Notable advancements in drug commercialization include the launch of Novo Nordisk's oral GLP-1 weight loss drug Wegovy in the U.S., with monthly costs ranging from $149 to $299 for self-paying patients [13][14]. - Moderna has submitted a New Drug Application (NDA) for its seasonal flu vaccine mRNA-1010, showing promising efficacy results in clinical trials [15]. - Arrowhead has reported positive mid-stage results for its RNAi therapies ARO-INHBE and ARO-ALK7, demonstrating significant reductions in visceral and liver fat [16][17]. - GSK's hepatitis B drug Bepirovirsen has shown statistically significant functional cure rates in its Phase III trials [18]. - Recent approvals for innovative drugs in China include BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which addresses familial chylomicronemia syndrome [19][21]. Summary by Sections Market Performance - The Shenwan Pharmaceutical and Biological Index increased by 7.8%, ranking 6th among 31 Shenwan primary industries [2][3]. - Various sub-sectors showed positive growth, with medical devices and medical outsourcing leading with increases of 10.8% and 11.1%, respectively [5]. Industry Dynamics - The long-term care insurance system is set to expand significantly, with a focus on providing care for the elderly and disabled [11][12]. - The report emphasizes the importance of innovation in drug development, particularly in RNAi therapies and small nucleic acid drugs, which are gaining traction in clinical settings [16][18]. Company Developments - Significant partnerships and collaborations are highlighted, such as the $8.88 billion research collaboration between Insilico Medicine and Servier focusing on oncology [20]. - The report notes the successful commercialization of several new drugs, including BeiGene's and Sanofi's recent approvals, which are expected to impact market dynamics positively [19][21]. - The establishment of new companies and subsidiaries, such as the brain-computer interface subsidiary by Xinwei Medical, indicates a strategic shift towards innovative technologies in healthcare [22].

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating a "Buy" rating based on recent market performance and emerging opportunities in innovative drug development [2][3]. Core Insights - The pharmaceutical sector saw a significant increase, with the Shenwan Pharmaceutical and Biological Index rising by 7.8%, outperforming the Shanghai Composite Index, which increased by 3.82% [2][3]. - The report highlights the ongoing commercialization of innovative drugs, including the oral GLP-1 medication Wegovy by Novo Nordisk, and the successful clinical trials of various RNAi therapies [11][13][18]. - The establishment of a comprehensive long-term care insurance system in China is expected to enhance the healthcare landscape, potentially benefiting the pharmaceutical sector [11][12]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 6th among 31 Shenwan first-level sub-industries, with various sub-sectors showing positive growth, such as medical devices (+10.8%) and medical research outsourcing (+11.1%) [2][5]. - The overall valuation of the pharmaceutical sector stands at 30.6 times earnings, ranking 10th among 31 Shenwan first-level industries [5][10]. Recent Key Events - The report notes the successful approval and commercialization of several new drugs, including BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which address significant medical needs [20][22]. - Collaborations in drug development are highlighted, such as the $8.88 billion partnership between Insilico Medicine and Servier focusing on oncology [21]. - The report emphasizes the potential of the brain-computer interface industry, with companies like Mindray Medical and Lepu Medical making strides in this area [24]. Investment Opportunities - The report suggests focusing on domestic innovative drug companies and CROs, particularly those involved in the development of small nucleic acid drugs and brain-computer interface technologies [2][11]. - Specific companies to watch include Tigermed, WuXi AppTec, and Innovent Biologics, which are positioned to benefit from the recovery of the innovative drug sector [2][11].

黄金股普跌，金田跌4.5%，哈莫尼黄金跌3.6%。Ventyx Biosciences涨51.0%，礼来拟以超10亿美元收购 该公司。Mobileye涨17.2%，官宣9亿美元收购机器人公司Mentee。百济神州涨4.2%，新型BCL2抑制剂 百悦达在中国获上市许可。 ...

在经历一轮快速上涨、市场出现"过热"迹象之后，周三这波屡创新高的全球股市涨势开始失去动能，欧 股关注美国总统特朗普对格陵兰岛的态度。美国12月"小非农"人数低于预期。 截至发稿，道指期货涨0.04%，标普500指数期货跌0.08%，纳指期货跌0.24%。 ADP报告称，12月就业出现反弹，私营企业增加4.1万个就业岗位，低于市场预期中值4.7万人。教育和 医疗服务、休闲和酒店业领涨。 ADP首席经济学家Nela Richardson：小型企业从11月份的失业中恢复过来，年底招聘人数增加，尽管大 型雇主在收缩。 欧洲股市涨跌互见，泛欧斯托克600指数几乎没有变化，各板块和主要地区股市涨跌互现。美国总统特 朗普威胁吞并格陵兰岛，导致地区市场紧张情绪加剧。 随着美国的军事行动导致委内瑞拉领导人马杜罗被捕，特朗普总统对丹麦自治领土格陵兰岛的意图引起 了全球市场的关注。白宫新闻秘书卡洛琳·莱维特周二告诉CNBC，总统和他的团队正在考虑收购格陵兰 岛的"一系列选择"，包括"利用美国军队"。 特朗普坚持认为，美国需要这个北极岛屿用于国家安全目的，本周，他指出了俄罗斯和中国在该地区的 活动。对此，格陵兰岛和丹麦都一再表示，格 ...